TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01336010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
Study: NCT01715805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules 1.5 to 4.5 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dose-matched placebo capsule once per day
Study: NCT00489489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study: NCT01715805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo capsule once per day

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dose-matched placebo capsule once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study: NCT03741608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High blood pressure management education
Description: The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
Study: NCT01715805

Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study: NCT02498600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03913611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation protocol
Description: Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional rehabilitation protocol
Description: Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
Study: NCT01673932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCBMC
Description: Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCBMC
Description: Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT02392429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given anthracycline IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FLT PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FLT PET/CT
Study: NCT04746690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius
Description: neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius
Description: neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius
Description: neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
Study: NCT03685253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
Study: NCT01601119

Intervention type: DRUG
Intervention: Rebif
Description: The subjects will receive Rebif as per the current practices or as directed by the physician.

Intervention type: OTHER
Intervention: Other: Disease modifying therapies (DMT)
Description: The subjects will receive other DMTs as per the current practices or as directed by the physician.
Study: NCT03622060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: 200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal
Study: NCT04293341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavior Therapy
Description: TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy for PTSD
Description: CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for MDD
Description: CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
Study: NCT03481868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of blood and bone marrow
Description: Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
Study: NCT04293341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Panic Disorder
Description: CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
Study: NCT01808599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab s.c.
Study: NCT00435708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 portions fruit and vegetables/day
Description: Participants consume \> = 5 portions fruit and veg per day
Study: NCT04521179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 combination
Description: 30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
Study: NCT04358185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib (INCB039110)
Description: Novel and small molecule selective inhibitor of JAK1
Study: NCT04628390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
Study: NCT04537234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM
Study: NCT01304511

Intervention type: DRUG
Intervention: Orgalutran
Study: NCT04483791

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: DynamX Novolimus Eluting Coronary Bioadaptor System
Description: up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
Study: NCT01503515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin Acetate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT03741608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home blood pressure measurement
Description: Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
Study: NCT05639387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: actual tVNS
Description: Active tVNS (stimulation on cymba conchae --\> nervus vagus stimulation)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham tVNS
Description: Sham tVNS (stimulation on earlobe --\> no nervus vagus stimulation)
Study: NCT04039581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping relaxation technique (muscle inhibition technique)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio Taping relaxation technique (muscle inhibition technique)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
Study: NCT03539315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARCHES
Description: Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
Study: NCT00922454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Repair of the abdominal aorta
Description: Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Repair of the abdominal aorta
Description: Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Zenith Stent-Graft
Description: Cook Zenith AAA Endovascular Graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Talent Stent-Graft
Description: Talent AAA Abdominal Stent Graft System
Study: NCT04166357

Intervention type: DIAGNOSTIC_TEST
Intervention: neuromuscular ultrasound
Description: Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
Study: NCT06390839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT03194802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleeping Without Pills Program
Description: Participants receive this program online and are asked to log in daily for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Participants enter sleep diary data online daily for 6 weeks
Study: NCT00517738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: A program of exercising under strict surveillance, with endurance and coordination maneuvers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: A program of exercising under strict surveillance, with endurance and coordination maneuvers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention
Description: Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention
Description: Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
Study: NCT01921673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib and docetaxel
Description: In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used.
Study: NCT01792063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT02868359

Intervention type: OTHER
Intervention: No Intervention
Description: The study is observational.

Intervention type: OTHER
Intervention: No Intervention
Description: The study is observational.
Study: NCT03664687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Administered intravenously (IV)
Study: NCT00533377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-533, 536
Description: Active study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Standard surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-533,536
Description: Active study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-533,536
Description: Active study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-533,536
Description: Active study drug
Study: NCT00410722

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole wheat and bran muffin
Study: NCT01952535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04954118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal jugular vein cannulation
Description: The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal jugular vein cannulation
Description: The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.